Press Release: Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

 and diluted common share                    ($0.51)          $0.41 
                                          =========       ========= 
 
Weighted average common shares 
 outstanding - basic and diluted             50,902          49,160 
                                          =========       ========= 
 
 
                                           7/31/2024       7/31/2023 
Selected balance sheet data:             (unaudited)     (unaudited) 
-----------------------------------   --------------  -------------- 
 
Cash and cash equivalents (includes 
 restricted cash of $1,000 at 
 7/31/23)                              $     52,371    $     83,373 
 
Working capital                              45,237          58,467 
 
Stockholders' equity                         56,112          78,462 
 
Total assets                                 85,764         121,880 
 
 
 
  The following table presents a reconciliation of 
reported net loss and basic and diluted net loss per 
  share to Adjusted net loss and Adjusted basic and 
  diluted net loss per share for the twelve months 
                ended July 31, 2024. 
 
                 ENZO BIOCHEM, INC. 
            Non-GAAP Reconciliation Table 
  (Unaudited, in thousands, except per share data) 
 
                                                         Twelve months ended 
                                                              July 31, 
                                                       ----------------------- 
                                                                 2024 
                                                            -------------- 
 
Reported GAAP loss                                       $         (26,078) 
Adjusted for: 
     Discrete legal matters                                          2,377 
     Fair value adjustment                                           1,095 
     Discrete separation expenses                                    1,742 
     Net loss from discontinued operations                          16,261 
Adjusted net loss                                        $          (4,603) 
                                                       ===  ============== 
 
 
Weighted Shares Outstanding: 
Basic and diluted                                                   50,902 
 
Basic and diluted earnings per share: 
Basic and diluted net loss per share GAAP                           ($0.51) 
 
Basic and diluted net loss per share non-GAAP                       ($0.09) 
 
 
 
The following table presents a reconciliation of 
  reported GAAP net loss for the twelve months 
   ended July 31, 2024 to EBITDA and Adjusted 
                     EBITDA: 
 
               ENZO BIOCHEM, INC. 
  EBITDA & Adjusted EBITDA Reconciliation Table 
            (Unaudited, in thousands) 
 
                                                     Twelve months ended 
                                                           July 31, 
                                                   ------------------------- 
                                                             2024 
                                                        -------------- 
 
GAAP net loss                                        $         (26,078) 
Plus (minus): 
    Depreciation and amortization                                1,272 
    Interest (income) expense, net                              (3,341) 
    Income tax benefit - discontinued operations                  (390) 
EBITDA                                                         (28,537) 
 
Adjusted for: 
    Discrete legal matters                                       2,377 
    Fair value adjustment                                        1,095 
    Discrete separation expenses                                 1,742 
    Net loss from discontinued operations before 
     income tax benefit                                         16,651 
    Foreign exchange loss                                          192 
Adjusted EBITDA                                      $          (6,480) 
                                                   ===  ============== 
 
 

(END) Dow Jones Newswires

October 29, 2024 19:59 ET (23:59 GMT)